---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-258156"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2023-10-18T23:59:59+00:00"
generated_at: "2026-06-09T21:36:46.529239+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics appoints Michelle Yanez as director, forms Scientific Advisory Board

## Summary
- Michelle Yanez appointed as independent director and Audit Committee member, effective Oct 13, 2023.
- Company creates SAB to advise on clinical development; Dr. Elizabeth Billingsley named chairperson.
- Consulting agreement with Dermapharm Consulting LLC (Dr. Billingsley) at $600/hour for clinical trial support.

## SEC filing metadata
- accession: 0001193125-23-258156
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2023-10-18T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/0001193125-23-258156-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/d562103d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-258156
- JSON: https://secwatch.observer/filing/0001193125-23-258156.json
- Plain text: https://secwatch.observer/filing/0001193125-23-258156.txt

## Key facts
- Executive change
  Michelle Yanez was appointed as Director at Inhibitor Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On October 13, 2023, the Board of Directors (the “ Board ”) of Inhibitor Therapeutics, Inc. (the “ Company ”) appointed Michelle Yanez to fill one of the vacancies of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1042418/000119312523258156/0001193125-23-258156-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.